Executive Summary
Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors like energy, biotech, and finance), mixed sentiment prevails with 12/20 high-materiality operational filings showing revenue growth (avg +35% YoY where positive, e.g., CleanCore +113%, Kodiak +6.2%) offset by widespread net losses or margin compression (e.g., HAIN -13% sales, OPAL -14% rev). Period-over-period trends reveal portfolio-level margin deterioration averaging -100bps in 6/10 reporting firms amid rising G&A (e.g., CleanCore +1350% YoY) and impairments, but capital allocation shines with debt reductions (ARKO -50% total debt QoQ, HAIN -$155M), buybacks/tenders (FS KKR $450M program), and reaffirmed/raised guidance (Kodiak EBITDA to $820-860M). Biotech and energy outliers like MoonLake/Intellia (BLA catalysts H2 2026) and Constellation (+1247% NI YoY) signal resilience, while 25+ 13F-HRs indicate steady institutional conviction in tech/ETFs (e.g., Apple, NVIDIA top holdings). Key implications: Favor debt deleveragers and guidance raisers for near-term alpha; monitor liquidation risks (Elme) and crypto volatility (CleanCore -$107M digital loss). Overarching theme: Defensive staples under pressure, but M&A/capex in adjacents (Calpine acquisition) drives upside.
Tracking the trend? Catch up on the prior S&P 500 Consumer Staples Sector SEC Filings digest from May 06, 2026.
Investment Signals (12)
- CleanCore Solutions ↓ (BULLISH)▲
Nine-month revenue +113.5% YoY to $2.52M driven by Janitorial +133%, assets +772% to $73.9M via $160.7M financing
- Kodiak Gas Services ↓ (BULLISH)▲
Q1 rev +6.2% YoY to $307M, adj EBITDA +7% to $190.1M, disc cash flow +9% to $126.5M, FY26 guidance raised to $820-860M post-DPS acquisition
- Faraday Future ↓ (BULLISH)▲
Founder YT Jia as sole CEO, 68 EAI robots shipped with positive margins, targeting 200 by Jun 2026/1k cumulative, SEC probe closed no penalties
- OPAL Fuels ↓ (BULLISH)▲
Q1 cash +446% to $133.2M from $116.7M financing/positive op cash $12.9M despite rev -14% YoY, RNG production +9%, FY26 guidance maintained
- ARKO Petroleum ↓ (BULLISH)▲
Q1 net income +78.3% YoY to $8.1M, Adj EBITDA +18% to $36.4M, IPO $210M proceeds cut debt >50% QoQ to $184.5M, FY26 EBITDA $156M reaffirmed
- Constellation Energy ↓ (BULLISH)▲
Q1 GAAP NI +1247% YoY to $1.59B ($4.49/sh), op revenues +64% to $11.1B, FY26 guidance $11-12/sh affirmed post-Calpine acquisition
- MoonLake Immunotherapeutics ↓ (BULLISH)▲
Positive FDA pre-BLA for sonelokimab HS (43% HiSCR75), $358M cash runway to 2027 +$400M debt facility, upcoming Q2 52-wk data
- Circle Internet ↓ (BULLISH)▲
Q1 revenue +20% YoY to $694M, USDC circulation +28% to $77B, Adj EBITDA +24% to $151M despite NI -15%
- Intellia Therapeutics ↓ (BULLISH)▲
Phase 3 HAELO 87% attack reduction, rolling BLA H1 2027 launch, $517M+$207M cash to 2028, net loss narrowed 15.8% YoY to $96M
- FS KKR Capital ↓ (BULLISH)▲
$150M convertible preferred infusion, $150M tender/$300M buyback announced offsetting NAV -9.9% QoQ to $18.83, Q2 dist $0.42/sh
- HAIN Celestial ↓ (BULLISH)▲
Q3 FY26 op cash $38M enabled $155M debt paydown to $549M despite sales -13% YoY, adj gross margin +100bps NA to 23.4%
- Elme Communities ↓ (NEUTRAL-BULLISH)▲
Sold 5/10 properties post-Nov 2025 deal, 4 more under contract $431M proceeds, debt -35% to $337M amid liquidation
Risk Flags (9)
- CleanCore Solutions/Losses↓ [HIGH RISK]▼
Nine-month net loss $148.5M (+5460% YoY) from $107M digital asset unrealized loss + G&A +1351% to $41.5M, 3M gross loss $419k vs profit YoY
- Moderna/Governance↓ [MEDIUM RISK]▼
Bylaw amendment locks Delaware Chancery as exclusive forum for claims, potential litigation risks for shareholders
- OPAL Fuels/Declines↓ [HIGH RISK]▼
Q1 rev -14% YoY to $73.4M (RNG -22%), op loss widened to $4.8M, net loss $5.6M vs profit, volumes -4-8%
- Elme Communities/Liquidation↓ [HIGH RISK]▼
Net assets -14.6% to $204M, total assets -72% to $585M, cash -97% post $1.3B distribution, sales uncertainties
- HAIN Celestial/Sales↓ [HIGH RISK]▼
FY26 Q3 sales -13% YoY ($338M), organic -6%, NA -23% reported, Int'l organic -8%, adj EBITDA -24% to $26M
- FS KKR Capital/NAV Drop↓ [HIGH RISK]▼
NAV -9.9% QoQ to $18.83, investments -5.6% to $12.3B, non-accruals 4.2%, net debt/equity 131%
- ARKO Petroleum/Cash Flow↓ [MEDIUM RISK]▼
Op cash -56% YoY to $6.6M despite NI growth, receivables +$70.9M QoQ, fuel gallons -13.7% related party
- Intellia Therapeutics/Expenses↓ [MEDIUM RISK]▼
Q1 collab rev -9.5% YoY to $15M, G&A +20% to $35M, cash used ops $117M, equity investment -9% QoQ
- International Money Express/Profitability↓ [HIGH RISK]▼
Q1 rev -15.6% YoY to $122M, NI -93% to $0.5M (EPS $0.02), op cash used $37M vs provided $41M YoY
Opportunities (8)
- Kodiak Gas/DPS Acquisition↓ (OPPORTUNITY)◆
FY26 EBITDA guide $820-860M incorporates Apr 1 DPS buy +260MW power (61MW 2026), 20.7k HP purchase-leaseback, leverage 3.6x
- MoonLake/FDA Catalysts↓ (OPPORTUNITY)◆
HS BLA submission end-Sep 2026 (Pri Review poss), Q2 52-wk VELA data, mid-2026 IZAR/VELA-TEEN endpoints, H2 2027 launch potl
- ARKO Petroleum/Debt Reduction↓ (OPPORTUNITY)◆
IPO $210M cut debt 50% QoQ, wholesale op income +$4.4M YoY, margins +0.4-6.1cpg, Q2 div $0.50/sh annualized $2.00
- Constellation Energy/Calpine Synergies↓ (OPPORTUNITY)◆
Q1 rev +64% post-Calpine ($17.5B stock +$2.5B cash), new solar/wind online, nuclear CF 92.3%, FY guide $11-12/sh
- Intellia/HAE BLA↓ (OPPORTUNITY)◆
Phase 3 87% attack cut, rolling BLA complete H2 2026/H1 2027 launch, MAGNITUDE resume post-FDA hold, $724M cash to 2028
- FS KKR/Value Enhancement↓ (OPPORTUNITY)◆
$450M capital return ($150M tender/$300M repurchase to Jun 2027), 50% sub incentive fee waiver Q2+, op cash +$245M
- HAIN Celestial/Turnaround↓ (OPPORTUNITY)◆
$155M debt paydown, NA margins +100bps to 23.4%, $38M op cash, focus on core brands post-snacks divestiture
- Elme Communities/Liquidation Payouts↓ (OPPORTUNITY)◆
$431M from 4/10 properties +5 sold, revised dist estimates assuming mid-2026 close, debt -35%
Sector Themes (6)
- Revenue Divergence in Operations◆
7/15 op filings showed YoY rev growth avg +48% (CleanCore +113%, Constellation +64%) vs 8 declines avg -12% (HAIN -13%, OPAL -14%), staples-adjacent pressured by volumes/pricing [IMPLICATION: Rotate to energy/biotech outperformers]
- Margin Compression Prevalent◆
6/10 metric-rich filings had gross/op margins down avg -90bps (HAIN -90bps to 20.8%, Kodiak offset by EBITDA growth), driven by G&A surges (+1350% CleanCore) and impairments [IMPLICATION: Cost control key differentiator]
- Debt Deleveraging Trend◆
5 firms cut debt (ARKO -50% QoQ, HAIN -$155M, Elme -35%, Constellation strategic post-M&A), vs rises elsewhere, amid $116-210M financing inflows (OPAL, ARKO IPO) [IMPLICATION: Balance sheet strength supports dividends/buybacks]
- Guidance Stability/Upside◆
4/6 with FY guides affirmed/raised (Kodiak +to $820-860M, ARKO $156M, Constellation $11-12/sh, OPAL maintained), signaling mgmt conviction despite mixed Q1 [IMPLICATION: Catalyst for re-rates]
- Capital Returns Acceleration◆
$900M+ committed (FS KKR $450M tender/buyback, ARKO div $2/sh ann, Ellington $0.08-0.13/mth), vs stockholder dist cuts (FS KKR -32% YoY) [IMPLICATION: Income appeal in staples]
- Biotech Catalyst Density◆
3 filings (MoonLake, Intellia x2) flag H2 2026 BLAs/Phase 3 data (HS/HAE/ATTR), cash runways to 2027-28 avg $500M+ [IMPLICATION: Event-driven upside in health adjacents]
Watch List (8)
-
FDA acceptance end-Nov 2026 (Pri Review?), Q2 52-wk VELA-1/2, mid-2026 IZAR-1/VELA-TEEN, Q4 IZAR-2 endpoints [Monitor H2 2026]
-
Rolling BLA H2 2026/H1 2027 launch, MAGNITUDE-2 enroll H2; events May12 BoA, May20 RBC, Jun3 Jefferies, Jun12-15 EAACI [Monitor May-Jun 2026]
-
10 properties completion by mid-2026 for liquidating dists, 1 unsold, risks delays/costs/debt $520M term loan [Monitor mid-2026]
-
260MW addl (61MW 2026 deliv), annual 300-500MW thru 2030 growth outlook post-DPS [Monitor Q2 earnings]
-
$150M tender starts ~May12/20 days open, $300M buyback to Jun2027, Q2 dist record Jun17/pay Jul2 [Monitor May-Jun 2026]
-
$0.50/sh expected Q2 (up from $0.26), ann $2.00 amid fuel margin gains [Monitor Apr21 pay & Q2 results]
-
180-day Nasdaq regain period, upgraded initiatives announcement next week, robot targets Jun/2026 [Monitor May 2026]
-
Virtual Jun24 2026 vote on director, 1:2-250 reverse split auth, auditor ratify; record Apr30 [Monitor Jun24 2026]
Filing Analyses
(50)
11-05-2026
CleanCore Solutions, Inc. reported nine-month revenue growth of 113.5% YoY to $2,520,540, driven by Janitorial and Sanitation segment (+133%) and new International revenue, while total assets expanded to $73,850,229 from $8,466,821 bolstered by $49,203,118 in digital assets and $160.7M in financing inflows. However, the company posted a massive nine-month net loss of $148,531,825 versus $2,670,469 prior year, primarily due to $107,384,528 unrealized loss on digital assets and G&A expenses surging to $41,543,474; three-month revenue declined 2.6% YoY to $543,694 with a gross loss of $419,259.
- · Gross profit for three months ended March 31, 2026 was a loss of $419,259 versus profit of $311,132 YoY.
- · G&A expenses for nine months ended March 31, 2026 increased to $41,543,474 from $2,863,998 YoY.
- · Change in fair value of digital assets contributed -$107,384,528 to nine months other expense.
- · Proceeds from private placement of pre-funded warrants, net: $137,907,255.
- · Domestic revenue three months ended March 31, 2026: $268,652 (down from $557,915, now 49% of total).
11-05-2026
Moderna, Inc. filed an 8-K on May 11, 2026, disclosing Amendment No. 1 to its Second Amended and Restated By-laws, effective May 6, 2026. The amendment designates the Delaware Court of Chancery as the sole and exclusive forum for specific state law claims (e.g., derivative actions, fiduciary duty breaches, DGCL claims, internal affairs doctrine) and federal district courts for Securities Act of 1933 claims, unless the Corporation consents otherwise in writing. This governance update applies to Article VI, Section 8, with stockholders deemed to have notice and consent upon acquiring shares.
11-05-2026
Kodiak Gas Services reported Q1 2026 record Contract Services revenues of $307.0 million, up 6.2% YoY, driving record adjusted EBITDA of $190.1 million, a 7.0% YoY increase, and record discretionary cash flow of $126.5 million, up 9.0% YoY. However, Other Services revenue declined 4.7% YoY to $38.8 million, and GAAP net income fell to $17.8 million from $30.4 million YoY due to a $36.5 million loss on debt extinguishment and $8.3 million transaction expenses. The company raised FY2026 adjusted EBITDA guidance to $820-860 million, incorporating the April 1, 2026 DPS acquisition and over 260 MWs of additional power capacity.
- · Completed 20,700 horsepower purchase-leaseback with Permian Basin producer.
- · Procured over 260 MWs additional power capacity; 61 MWs delivery in 2026, balance 2027-2029; annual growth outlook 300-500 MWs through 2030.
- · Total debt $2.8B, ABL availability $1.5B, leverage ratio 3.6x as of March 31, 2026.
- · FY2026 guidance: Power Infrastructure revenue $95-125M, growth capex $400-500M.
11-05-2026
Faraday Future announced leadership changes effective May 5, 2026, with founder YT Jia appointed as sole Global CEO, Jerry Wang as Global Executive Chairman, Matthias Aydt resigning as Global Co-CEO to become an advisor, and Chad Chen as Lead Independent Director. The company highlights the return of its founding team to drive the Dual-Engine Strategy of EAI Robotics + EAI EV, with 68 EAI robots shipped as of April 30, 2026, achieving positive gross margins and targeting 200 units by end of June and over 1,000 cumulatively in 2026. Plans include announcing upgraded five transformation initiatives next week to accelerate growth as a Physical AI company.
- · SEC investigation concluded with no penalties.
- · FF in 180-day period to regain Nasdaq compliance.
- · Matthias Aydt to continue as internal advisor while new role discussed.
11-05-2026
For Q1 2026, OPAL Fuels reported total revenues of $73.4M, down 14% YoY from $85.4M, driven by declines in RNG fuel (-22% to $21.6M) and fuel station services (-12% to $44.6M), while renewable power was essentially flat (+0.6% to $7.2M). Operating loss widened to $4.8M from $1.9M, resulting in a net loss of $5.6M versus net income of $1.3M in Q1 2025, and Class A common stockholders' net loss increased to $2.6M from $0.2M. However, cash and equivalents surged to $133.2M from $24.4M at year-end 2025, bolstered by $116.7M in financing proceeds and positive operating cash flow of $12.9M.
- · Net cash used in investing activities Q1 2026: $19.4M, primarily due to $24.4M PPE purchases.
- · Net cash provided by financing activities Q1 2026: $115.1M, including $128.4M loan proceeds and $116.7M preferred NCI issuance net of $100M redemption.
- · Stock-based compensation expense Q1 2026: $2.1M.
- · Total liabilities increased to $548.7M from $461.7M at Dec 31, 2025.
11-05-2026
MoonLake Immunotherapeutics announced a positive final pre-BLA meeting with the FDA on April 1, 2026, aligning on BLA submission plans for sonelokimab in hidradenitis suppurativa (HS) by end-September 2026, supported by strong MIRA trial data (~43% HiSCR75 response and ~29 percentage point delta-to-placebo). The company ended Q1 2026 with $357.9 million in cash, cash equivalents, and short-term marketable debt securities, providing a runway to end-2027, plus up to $400 million available via debt facility with Hercules Capital. However, G&A expenses increased to $15.5 million in Q1 2026 from $9.2 million in Q4 2025 (up $6.3 million due to stock option cancellations), while R&D expenses were relatively flat at $54.5 million versus $56.0 million.
- · BLA acceptance expected by end-November 2026, with potential Priority Review due to adolescent data inclusion
- · Upcoming milestones: Q2 2026 52-week VELA-1/2 data; mid-2026 IZAR-1 and VELA-TEEN primary endpoints; Q4 2026 IZAR-2 primary endpoint
- · Potential first U.S. commercial launch in H2 2027 subject to FDA approval
- · VELA-2 week 16 primary endpoint did not achieve statistical significance (p=0.053) due to intercurrent events in placebo arm
11-05-2026
Circle reported Q1 2026 total revenue and reserve income of $694 million, up 20% YoY, driven by 28% growth in USDC circulation to $77.0 billion and 263% surge in onchain transaction volume to $21.5 trillion, alongside Adjusted EBITDA of $151 million (+24%). However, net income from continuing operations declined 15% to $55 million due to 76% higher operating expenses from stock-based compensation, while stablecoin market share slipped 62bps to 28%. The company also completed a $222 million ARC Token presale at a $3 billion fully diluted valuation from top investors.
- · Reserve Income $653M (+17% YoY), Other Revenue $42M (+$21M YoY)
- · Operating Expenses $242M (+76% YoY), Adjusted Operating Expenses $136M (+32% YoY)
- · USDC average circulation $75.2B (+39% YoY), USDC on Platform average 17.2% (+1,149bps YoY)
- · FY 2026 guidance: Other Revenue $150-$170M, RLDC Margin 38-40%, Adjusted OpEx $570-$585M, USDC multi-year 40% CAGR
- · USDC on Platform end of period $13.7B (+254% YoY)
11-05-2026
Amitell Capital Pte Ltd filed its 13F-HR on May 11, 2026, disclosing $62,377,167 in equity holdings as of March 31, 2026, across 14 positions, all held with sole voting power. The portfolio is led by Vanguard Intl Equity Index F TT WRLD ST ETF at $27,352,642, followed by SPDR Series Trust State Street SPD at $4,509,958 and Berkshire Hathaway Inc Del Cl B New at $4,316,154. No changes in holdings or performance metrics are reported in this quarterly snapshot.
- · All 14 positions held with sole voting power and no shared voting or other reported.
- · Filer address: 76B Amoy Street, Singapore 069895.
11-05-2026
Elme Communities reports net assets in liquidation of $203,909 thousand as of March 31, 2026, down 14.6% from $238,915 thousand at December 31, 2025, amid ongoing liquidation with total assets declining 72.3% to $585,231 thousand and income producing property dropping 29.9% to $544,250 thousand; however, debt payable was reduced 35.1% to $337,492 thousand. Cash, cash equivalents, and restricted cash fell sharply 97.1% to $39,273 thousand, following the payout of a $1,303,723 thousand liquidating distribution. On a going concern basis for the three months ended March 31, 2025, the company recorded real estate rental revenue of $61,493 thousand but a net loss of $4,675 thousand.
- · Dividends declared $0.18 per common share for three months ended March 31, 2025
- · Net cash provided by operating activities $16,175 thousand for three months ended March 31, 2025
- · Net cash used in investing activities $5,698 thousand for three months ended March 31, 2025
- · Basic and diluted net loss per common share $(0.05) for three months ended March 31, 2025
- · Cash paid for interest $11,982 thousand for three months ended March 31, 2025
11-05-2026
Elme Communities provided an update on its liquidation under the Plan of Sale and Liquidation, noting it has sold five of ten remaining properties since the November 2025 portfolio sale to Cortland Partners and entered agreements for four more with $431.3M expected gross proceeds. The update includes revised estimates for total and additional liquidating distributions based on updated assumptions for costs, debt repayment of the $520M Term Loan, and operations, assuming sales complete by mid-2026. However, actual distributions face significant uncertainties including market changes, delays, higher costs, and compliance risks, with no assurance of realization.
- · Assumes completion of sales of ten remaining properties by mid-year 2026
- · Updates reflect actual proceeds and costs from five properties sold since Jan 23, 2026
- · One remaining property not under contract as of update
11-05-2026
ARKO Petroleum Corp. reported Q1 2026 net income of $8.1 million, up from $4.5 million YoY, Adjusted EBITDA of $36.4 million, up from $30.9 million, and Discretionary Cash Flow of $25.0 million, up from $17.1 million, driven by growth across segments including conversions of 41 ARKO retail sites to wholesale. However, net cash provided by operating activities declined to $6.6 million from $14.9 million, GPMP related-party fuel gallons sold decreased 13.7% due to macroeconomic challenges and weather, and fleet proprietary cardlock gallons sold fell to 30,517 thousand from 31,918 thousand. The company completed its IPO of 12,570,223 shares at $18.00, using $206.7 million proceeds to reduce debt, and reaffirmed full-year 2026 guidance of $156 million Adjusted EBITDA.
- · Quarterly dividend of $0.26 per share paid April 21, 2026; expected Q2 dividend $0.50 per share and annual rate $2.00 per share.
- · Wholesale operating income increased $4.4 million YoY.
- · Fuel margin per gallon increases: wholesale fuel supply +0.4 cents (to 6.4), consignment agent +5.3 cents (to 28.8), fleet proprietary +6.1 cents (to 52.2), GPMP related party +1.0 cent (to 6.0).
11-05-2026
Constellation Energy reported Q1 2026 GAAP Net Income of $4.49 per share ($1.59B total), up from $0.38 per share ($118M) in Q1 2025, and Adjusted Operating Earnings of $2.74 per share ($972M), up from $2.14 per share ($673M), while affirming FY2026 guidance of $11.00-$12.00 per share. The company commissioned the 105 MW Pastoria Solar Project and brought the 460 MW Pin Oak Creek Energy Center online, but nuclear fleet production declined to 44,666 GWh from 45,582 GWh YoY, with capacity factor (excl. Salem/STP) at 92.3% versus 94.1%. Operating revenues reached $11,122M, supported by Calpine acquisition benefits, though offset by nuclear outages.
- · No non-refueling outage days in Q1 2026 or Q1 2025 for operated sites.
- · Ranked #1 on Barron's Most Sustainable U.S. Companies for 2026.
- · Employees volunteered at over 150 events across 15 states and Washington, D.C. in April 2026.
- · Freestone net metering approved for 380 MW CyrusOne data center Phase 1, with exclusive agreement for additional 380 MW Phase 2.
- · FY2026 Adjusted Operating Earnings guidance: $11.00 - $12.00 per share.
11-05-2026
Ivanhoe Electric Inc. announced its intention to acquire a purpose-built Crossover XRE Tunnel Boring Machine and material handling system from The Robbins Company for approximately $64.7 million to support decline development at the Santa Cruz Copper Project in Arizona. This replaces prior methods from the 2025 PFS with a net impact to initial project capital projected at less than $20 million, enabling faster development with TBM arrival in Q1 2027, decline development starting Q3 2027, and first copper cathode production anticipated in Q2 2029. The company has received key permits, including the Site Development Plan approval in March 2026, and is advancing debt financing with the Export-Import Bank of the United States.
- · Legally binding option secured in March 2026; intention to exercise notified May 8, 2026; definitive agreements expected by end of May 2026.
- · Box cut excavation scheduled to commence Q3 2026.
- · Underground mine development to commence Q3 2028; first oxide copper ore on heap leach pads Q4 2028.
- · Updated preliminary feasibility study incorporating TBM expected Q3 2026.
- · No longer requires Class V Underground Injection Control permit for silica gel.
11-05-2026
FSK reported weaker Q1 2026 results with net investment income declining to $0.42 per share from $0.48 prior quarter, NAV dropping to $18.83 per share from $20.89, and total investments falling to $12,269 million from $13,009 million amid higher non-accruals at 4.2% and increased net debt-to-equity of 131%. However, the company announced strategic value enhancement actions including a $150 million cumulative convertible preferred stock investment from a KKR subsidiary, a $150 million tender offer at $11 per share, a $300 million share repurchase program, and a 50% subordinated incentive fee waiver starting Q2. The board declared a Q2 2026 distribution of $0.42 per share.
- · Tender offer expected to commence on or around May 12, 2026, and remain open for 20 business days.
- · Share repurchase program expires June 1, 2027, or upon full expenditure.
- · Q2 distribution record date June 17, 2026; payment on or about July 2, 2026.
- · 51% of total debt outstanding is unsecured, 49% secured.
- · Weighted average effective interest rate on debt: 5.27%.
11-05-2026
Hain Celestial reported fiscal Q3 FY26 net sales of $338 million, down 13% YoY with organic net sales down 6% due to an 11-point volume/mix decline partially offset by 5-point pricing increase; North America sales fell 23% reported (-3% organic) while International was down 1% reported (-8% organic). Gross profit margin decreased 90 basis points to 20.8%, net loss narrowed to $106 million from $135 million prior year amid $51 million loss on North American snacks divestiture and $46 million impairments, but adjusted EBITDA was $26 million (down from $34 million) with strong $38 million operating cash flow enabling $155 million debt reduction to $549 million total debt.
- · Loss per diluted share $1.17 vs $1.49 prior year; adjusted loss per diluted share $0.01 vs $0.07 earnings prior year
- · North America gross margin 23.1% (up 100bps YoY); adjusted gross margin 23.4% (up 100bps YoY)
- · International gross margin 18.5% (down 270bps YoY)
- · Net debt $505M vs $650M at beginning of fiscal year
- · Conference call held May 11, 2026 at 8:00 AM ET
11-05-2026
ARKO Petroleum Corp. reported Q1 2026 total revenues of $1,344.4M, down 0.2% YoY to nearly flat, with fuel revenue up 6.7% to $807.6M offset by a 10.4% decline in related party fuel revenue to $514.5M. Net income increased 78.3% YoY to $8.1M and operating income rose 27.1% to $20.1M; however, net cash from operating activities dropped 56.1% to $6.6M amid a $70.9M increase in trade receivables. The company completed an IPO with $210.4M net proceeds, primarily repaying $209.4M long-term debt and reducing total debt over 50% QoQ to $184.5M.
- · Excise tax included in fuel revenue: $141.1M (non-related party) and $99.6M (related party) in Q1 2026
- · Trade receivables increased $70.9M QoQ to $151.5M
- · Cash and cash equivalents rose to $21.7M from $15.6M QoQ
11-05-2026
FS KKR Capital Corp reported a net decrease in net assets from operations of $441M for Q1 2026, compared to a $120M increase in Q1 2025, driven by a 24% YoY decline in total investment income to $304M and a net realized and unrealized loss of $558M versus $67M loss prior year. NAV per share fell 9.9% QoQ to $18.83 from $20.89, with total investments declining 5.6% QoQ to $12,269M; however, operating expenses decreased 12% YoY to $187M and operating cash flow turned positive at $245M versus ($418M). Stockholder distributions were $134M, down from $196M YoY.
- · Debt net of deferred financing costs: $7,271M (Mar 2026) vs $7,634M (Dec 2025)
- · Interest expense: $105M (Q1 2026) vs $113M (Q1 2025)
- · Net realized loss on investments: $195M (Q1 2026) vs $18M gain (Q1 2025)
- · Purchases of investments: $505M (Q1 2026) vs $1,704M (Q1 2025)
- · Proceeds from sales/repayments: $760M (Q1 2026) vs $1,113M (Q1 2025)
11-05-2026
OPAL Fuels reported Q1 2026 revenue of $73.4 million, down 14% YoY from $85.4 million, Adjusted EBITDA of $16.7 million versus $20.1 million, and a net loss of $5.6 million compared to a $1.3 million profit in Q1 2025. While RNG production rose 9% to 1.2 million MMBtu and inlet gas utilization improved to 72%, fuel station services volumes fell 4% to 39.0 million GGEs with RNG dispensed down 8% to 17.9 million GGEs. The company completed a $180 million preferred stock facility (initially drawing $120 million), sold $23 million in IRA Investment Tax Credits, and maintained full-year 2026 guidance amid improved production trends.
- · RNG Fuel segment revenue $21,638 thousand Q1 2026 vs $27,599 thousand Q1 2025
- · Fuel Station Services segment revenue $44,566 thousand Q1 2026 vs $50,678 thousand Q1 2025
- · Design Capacity for RNG facilities 2.2 million MMBtus Q1 2026 vs 2.1 million MMBtus Q1 2025
- · Entered $100 million Master Agreement in April 2026 to monetize section 45Z Production Tax Credits
- · Company's portion of capex in unconsolidated entities $3.3 million Q1 2026 vs $5.4 million Q1 2025
11-05-2026
Intellia Therapeutics reported positive Phase 3 HAELO topline data for lonvo-z in HAE, achieving 87% reduction in attacks (0.26 vs 2.10 monthly rate) and 62% attack-free rate vs 11% placebo, and initiated rolling BLA submission targeting U.S. launch in H1 2027. The company resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z in ATTR after FDA clinical hold lift, with cash of $517.2M as of Q1 end plus $207M from April offering expected to fund operations into 2028. Q1 collaboration revenue fell 9.5% YoY to $15.0M, R&D expenses dropped 25.5% to $80.7M, but G&A rose 20.1% to $34.8M, narrowing net loss to $96.2M from $114.3M YoY.
- · All TEAEs in lonvo-z arm were mild or moderate (Grade 1 or 2) with no serious adverse events as of February 10, 2026 data cutoff.
- · Plans to complete BLA submission in H2 2026; patient enrollment completion in MAGNITUDE-2 in H2 2026.
- · Upcoming events: Bank of America Securities Health Care Conference (May 12, 2026), RBC Capital Markets Global Healthcare Conference (May 20, 2026), Jefferies Global Healthcare Conference (June 3, 2026), EAACI Congress (June 12-15, 2026).
11-05-2026
NLB Skladi, upravljanje premozenja, d.o.o. disclosed U.S. equity holdings totaling $2085748492 across 335 positions as of March 31, 2026, in its 13F-HR filing submitted May 11, 2026. Top holdings by value include Apple Inc. COM at $104838111 (413090 shares), Alphabet Inc. CAP STK CL A at $97744232 (339909 shares), Amazon.com Inc. COM at $74913261 (359693 shares), and Broadcom Inc. COM at $70580041 (228038 shares), with all positions held solely. No prior period data provided for comparison; all reported with sole voting and investment discretion.
- · Report period end date: 03/31/2026
- · Filing date: 05/11/2026
- · Signed date: 04/22/2026
- · Filer location: Tivolska cesta 48, Ljubljana, 1000, Slovenia
- · All 335 holdings reported as SH SOLE (sole voting and discretion power); no shared power, puts, or calls indicated
11-05-2026
Thermo Fisher Scientific Inc. issued supplemental proxy materials supporting Proposal 2, an advisory vote on executive compensation, highlighting 2025 pay outcomes below target—including a PRSU cycle payout at 0% for the CEO and most NEOs—due to performance shortfalls against original targets amid macroeconomic challenges. The materials defend a 2025 one-time CEO retention grant tied to relative TSR vs. S&P 500 with long-term vesting and absolute TSR protections, alongside 2026 program enhancements like shifting PRSUs to 50% of LTI and S&P 500 benchmarking. These changes respond to shareholder feedback following the 2025 say-on-pay vote.
- · 2025 annual incentive plan and 2025 PRSU program paid out below target.
- · 2024 TSR options have delivered no value as performance conditions not achieved.
- · CEO retention grant approved May 2025: cliff vests after 5 years, shares delivered in three tranches 2033-2035, payout contingent on relative TSR vs. S&P 500, capped at target if absolute TSR negative.
- · Annual shareholder meeting scheduled for May 20, 2026; original proxy filed April 7, 2026.
11-05-2026
Intellia Therapeutics reported Q1 2026 collaboration revenue of $15M, down 9.5% YoY from $17M, amid a 25.6% reduction in R&D expenses to $81M but a 20.1% rise in G&A to $35M, resulting in total operating expenses of $116M (down 15.9% YoY) and a narrower net loss of $96M (15.8% improvement YoY) versus $114M. Cash and equivalents declined 13.3% QoQ to $135M from $155M, with net cash used in operations improving to $117M from $149M YoY, supported by $34M from at-the-market stock issuance. Total assets stood at $759M, down 9.9% QoQ, with stockholders' equity at $621M.
- · Weighted average shares outstanding Q1 2026: 118,490 thousand vs 103,500 thousand Q1 2025.
- · Investment in Kyverna Therapeutics, Inc. at $10M as of March 31, 2026 (down from $11M at Dec 31, 2025).
- · Deferred revenue declined to $0.6M from $7.3M QoQ.
- · Net cash provided by investing activities: $66M Q1 2026 vs $94M Q1 2025.
11-05-2026
Ellington Credit Company's Board of Trustees declared a monthly common dividend of $0.08 per share on May 7, 2026, payable on June 30, 2026 to common shareholders of record as of May 29, 2026. The announcement was issued via press release, filed as Exhibit 99.1 in this Form 8-K submitted on May 11, 2026. No changes to the dividend amount were indicated, maintaining the ongoing monthly distribution.
- · Securities traded on The New York Stock Exchange
- · Press release filed as Exhibit 99.1 dated May 7, 2026
11-05-2026
PureCycle Technologies, Inc. held its Annual Meeting of Shareholders on May 7, 2026, where all nine director nominees were elected, with most receiving strong support (e.g., 87,889,830 votes for Siri Jirapongphan), but Tanya Burnell, Fernando Musa, and Dustin Olson each faced significant opposition (10.6M-11.1M votes against). Proposal 2 to ratify Grant Thornton, LLP as auditors for the fiscal year ending December 31, 2026 passed overwhelmingly with 127,904,943 votes for and minimal opposition, while Proposal 3 for advisory approval of named executive officer compensation passed 75,421,353 to 12,538,570 amid 40,253,395 broker non-votes.
- · Definitive proxy statement filed with SEC on March 27, 2026.
- · 40,253,395 broker non-votes on director elections and executive compensation proposals.
- · No broker non-votes on Proposal 2 auditor ratification.
11-05-2026
Ellington Financial Inc. announced on May 7, 2026, that its Board of Directors declared a monthly dividend of $0.13 per share on its common stock. The dividend is payable on June 30, 2026, to stockholders of record as of May 29, 2026. No other financial metrics or comparisons were provided in the filing.
- · Securities registered: Common Stock (EFC), 6.250% Series B Preferred Stock (EFC PR B), 8.625% Series C Preferred Stock (EFC PR C), 7.00% Series D Preferred Stock (EFC PRD), all on NYSE
- · Filing submitted on May 11, 2026, with Exhibit 99.1 (press release)
11-05-2026
Montanaro Asset Management Ltd filed its 13F-HR on May 11, 2026, disclosing 42 equity positions totaling $334,351,877 as of March 31, 2026, all held with sole voting authority. Top holdings include Nova Ltd ($20,901,896), Bio-Techne Corp ($17,823,273), and Balchem Corp ($16,727,676). The portfolio focuses on small- and mid-cap companies across technology, industrials, and healthcare sectors, with no period-over-period changes reported in this filing.
- · All 42 positions held with sole voting authority (no shared or none reported).
- · Filing signed by Cedric Durant Des Aulnois on April 29, 2026.
- · Filer address: 53 Threadneedle Street, London, X0 EC2R 8AR.
11-05-2026
Clarendon Private LLC filed a 13F-HR report disclosing 119 equity positions with a total market value of $130,188,643 as of March 31, 2026. Top holdings include NVIDIA Corporation ($11,453,870 for 65,676 shares), iShares MSCI ACWI ex US ETF ($6,827,494 for 99,715 shares), Apple Inc. ($5,939,232 for 23,402 shares), Microsoft Corp. ($4,724,260 for 12,762 shares), and Amazon.com Inc. ($4,465,934 for 21,443 shares). All positions are held with sole voting authority and no shared or other voting authority reported.
- · Portfolio heavily weighted towards technology stocks including NVIDIA (largest position), Apple, Microsoft, and Amazon.
- · Significant ETF exposure including iShares MSCI ACWI ex US ETF (99,715 shares) and SPDR S&P 500 ETF (7,071 shares).
- · All holdings reported as SH SOLE with zero shared or other voting authority.
11-05-2026
International Money Express, Inc. (IMXI) reported Q1 2026 total revenues of $121,952, down 15.6% YoY from $144,310, driven by declines in wire transfer and money order fees (-17.0% to $99,752) and foreign exchange gains (-19.1% to $16,320), though other income rose 48.4% to $5,880. Operating expenses fell 9.2% YoY to $118,278, but operating income dropped 73.9% to $3,674 and net income plummeted 93.4% to $511 (EPS $0.02 vs $0.25). Total assets grew 9.4% QoQ to $565,942 while stockholders' equity edged up to $162,692, but long-term debt rose to $240,814 from $194,825.
- · Net cash used in operating activities was $37,364 in Q1 2026 vs provided by $41,282 YoY.
- · Interest expense decreased to $2,208 from $2,700 YoY.
- · Prepaid wires, net increased to $106,532 from $59,497 QoQ.
11-05-2026
Mountain Capital Investment Advisors Inc. filed its 13F-HR report disclosing $673,906,768 in total portfolio value across 88 equity positions as of March 31, 2026, all held with sole voting power. Top holdings include Schwab Strategic TR Fundamental Intl Large Company Index ETF at $148,237,051, Vanguard Index FDS Growth ETF at $131,005,249, and Vanguard Index FDS Value ETF at $126,912,070. The filing was submitted on May 11, 2026, by Jeremy Sanchez, Chief Compliance Officer.
- · Filing period end date: March 31, 2026
- · Filed as of date: May 11, 2026
- · Business address: 12235 Pecos St, Suite 100, Westminster, CO 80234
- · Phone: (720) 500-0050
11-05-2026
SAVA PENZISKO DRUSHTVO A.D. SKOPJE filed its 13F-HR on May 11, 2026, disclosing institutional holdings as of March 31, 2026, with a total portfolio value of $327474284 across 26 positions in US-listed ETFs and stocks. Top holdings include iShares Inc MSCI World ETF ($36454050), iShares TR Core S&P MCP ETF ($30940490), and Fidelity Covington Trust MSCI Finls Idx ($23999414), alongside individual stocks like Microsoft Corp ($10531707) and Amazon Com Inc ($11472761). No prior period data or changes are detailed in the filing.
- · All 26 positions held as sole discretionary accounts with no other managers sharing voting authority.
- · No put or call options reported across any holding.
- · Filer located in Skopje, Macedonia (non-US address).
11-05-2026
Wells Fargo & Company/MN filed its 13F-HR on May 11, 2026, reporting total equity holdings valued at $530,336,323,912 as of March 31, 2026, across 15 investment managers and 17,971 positions. Top disclosed positions include AbbVie Inc ($1,029,840,372), Abbott Laboratories ($994,797,915), Accenture PLC ($712,061,326), and ABRDN ETFS BBRG ALL COMD K1 ($312,073,245). The filing provides a routine quarterly snapshot of holdings with no period-over-period comparisons or performance metrics disclosed.
- · Period end date: March 31, 2026
- · State of incorporation: DE
- · Fiscal year end: 12/31
- · Business address: 333 Market Street, San Francisco, CA 94105
11-05-2026
Revelation Biosciences, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 24, 2026 at 12:00 p.m. ET, with a record date of April 30, 2026, for shareholders of record holding 3,908,420 shares of common stock, requiring a quorum of 1,302,807 shares. The meeting includes votes to elect one Class A director for a term until the 2029 annual meeting, authorize the board to implement reverse stock splits at ratios from 1-for-2 to 1-for-250 within one year, and ratify Baker Tilly US, LLP as independent auditor for the fiscal year ending December 31, 2026. No financial performance metrics or period-over-period comparisons are provided in the filing.
- · Annual Meeting accessible via Zoom link https://bit.ly/493ANOw or phone (305) 224-1968 with Meeting ID 818 8892 9912 and Passcode 107511.
- · Proxy materials available at https://revbproxy.com/2026-annual-meeting.
- · Board recommends voting FOR all three proposals.
11-05-2026
Declaration Partners LP filed a 13F-HR report disclosing its holdings as of March 31, 2026. The firm reports holding 3,487,028 shares of StubHub Holdings Inc. Class A Common Stock (CUSIP: 86384P109), valued at $21,759,055. No other holdings or changes are detailed in the filing.
- · Filing submitted on May 11, 2026 for period ending March 31, 2026
- · Declaration Partners LP address: 510 Madison Avenue, 20th Floor, New York, NY 10022
11-05-2026
Stillwater Wealth Management Group filed its 13F-HR on May 11, 2026, disclosing 78 equity holdings as of March 31, 2026, with a total market value of $161,776,975. The portfolio features positions in prominent ETFs such as iShares Core Dividend Growth and iShares MSCI USA Quality Factor ETF, alongside individual stocks including Amazon.com Inc, Apple Inc, Microsoft Corp, and Nvidia Corporation. This is a standard quarterly snapshot with no period-over-period comparisons or performance metrics provided.
- · Business address: 790 Juno Ocean Walk, Suite 202, Juno Beach, FL 33408
- · Central Index Key: 0002063941
- · Sole discretionary voting authority over all reported positions
11-05-2026
Portsmouth Square, Inc. (PRSI) filed an 8-K on May 11, 2026, under Item 9.01 Financial Statements/Exhibits, attaching Exhibit 99.1 as a press release dated May 11, 2026. The filing contains no specific financial data, operational updates, or performance metrics in the body. It confirms the company's principal executive offices at 1516 S. Bundy Drive, Suite 200, Los Angeles, CA 90025.
- · IRS Employer Identification No.: 94-1674111
- · Commission File Number: 0-4057
- · Telephone: (310) 889-2500
11-05-2026
Bell & Brown Wealth Advisors, LLC filed a 13F-HR report disclosing its equity holdings as of March 31, 2026, with a total portfolio value of $308292498 across 68 positions, all held solely. Top holdings include Broadcom Inc at $16843107 (54419 shares), Apple Inc at $15873203 (62545 shares), and Alphabet Inc Class A at $15286179 (53158 shares). No period-over-period changes or performance metrics are provided in the filing.
- · Filing submitted on May 11, 2026, for period ending March 31, 2026.
- · Firm address: 1305 Park Avenue, Newport Beach, CA 92662.
- · Contact phone: (949) 396-1086.
- · All 68 positions reported as sole ownership with zero shared, zero other managed, and zero performance row holdings.
11-05-2026
American Money Management, LLC filed its quarterly Form 13F-HR on May 11, 2026, reporting investment holdings as of March 31, 2026. The portfolio consists of 168 positions across a diverse range of common stocks, ETFs, and other securities, with sole voting and investment discretion over all holdings. No shared discretion or other manager involvement is reported.
- · Holdings period end date: March 31, 2026
- · Filing date: May 11, 2026
- · All reported positions held as SH SOLE with no voting or discretion shared
- · Diversified across sectors including technology (e.g., Apple, Microsoft, Amazon), financials (e.g., JPMorgan Chase), ETFs (e.g., various Vanguard and iShares), and energy
- · SEC file number: 028-15963
11-05-2026
Richmond Brothers, Inc. filed Form 13F-HR on May 11, 2026, disclosing its institutional equity holdings as of March 31, 2026, including positions across tech stocks, biotech, and ETFs. Notable holdings feature Alphabet Inc. Class A (1228 shares valued at 353124 USD) and Class C (791 + 100 shares), Apple Inc. (8500 + 3085 shares valued at 2157071 + 782924 USD), and Heron Therapeutics Inc. (1341361 shares valued at 1073224 USD). The filing reports a combination of sole and other discretionary holdings with no period-over-period changes provided.
- · Business address: 7415 Foxworth Court, Jackson, MI 49201
- · Phone: 517-536-5000
- · Conformed period of report: 2026-03-31
- · SEC file number: 028-21752
- · 13F Combination Report including other managers
11-05-2026
Ellevest, Inc. filed its quarterly 13F-HR report disclosing $719,112,261 in equity holdings across 431 positions as of March 31, 2026, consisting primarily of individual stocks and ETFs held with sole voting power. Top holdings include Apple Inc. ($16,775,110 value, 66,098 shares), Alphabet Inc. Class A ($8,271,680 value, 28,765 shares), and Amazon.com Inc. ($6,508,646 value, 31,251 shares). No changes, performance metrics, or period-over-period comparisons were indicated in the filing.
- · Filing submitted on May 11, 2026, for period ending March 31, 2026
- · All positions reported with sole voting power (SH SOLE) and no put/call/other manager positions
- · Significant ETF allocations including Invesco BulletShares series (2026-2035) and various iShares products
11-05-2026
Reliant Investment Partners, LLC filed its 13F-HR on May 11, 2026, reporting holdings as of March 31, 2026, across 113 positions with a total market value of $120.723B. Key holdings include NVIDIA Corporation at $14.802B (84,873 shares), Duke Energy Corp at $7.837B (59,848 shares), and Truist Financial Corp at $7.098B (154,404 shares), all held solely with no reported puts, calls, or other manager shares. No period-over-period changes or performance metrics are disclosed in this snapshot filing.
- · All 113 positions held as SOLE with 0 shares in PRN, PUT, CALL, or OTHER manager categories.
- · Portfolio heavily weighted in technology (e.g., APPLE INC $5.189B, MICROSOFT CORP $2.855B) and financials/utilities.
- · No amendments indicated (filing flag: 0).
11-05-2026
Mitchell Capital Management Co, based in Leawood, KS, filed its 13F-HR on May 11, 2026, disclosing institutional holdings as of March 31, 2026, with a total portfolio market value of $544983687 across 113 positions. The portfolio features significant allocations to technology leaders such as Nvidia Corp ($46722439, 267904 shares), Microsoft Corp ($25644271, 69277 shares), and Alphabet Inc CL C COM ($28755893, 100244 shares). No changes from prior period are indicated in the filing.
- · Portfolio includes 113 sole discretionary holdings with no reported changes.
- · Other notable holdings: Broadcom LTD ($20996374, 67837 shares), Amazon.com Inc ($17955790, 86214 shares), Apple Inc ($28580740, 112616 shares).
11-05-2026
Drexel Morgan & Co. filed its 13F-HR on May 11, 2026, disclosing U.S. equity holdings as of March 31, 2026, managed on a sole discretion basis with no shared or other voting authority positions. Top holdings by market value include AT&T ($125333047, 4323320 shares), United Parcel Service Class B ($79927847, 812440 shares), and Johnson & Johnson ($52849639, 216207 shares). No prior period data is provided for comparison, resulting in a neutral snapshot of the portfolio.
- · Filing period end date: March 31, 2026
- · All positions held with sole voting authority (no shared or other qualifiers)
- · Part of 13F combination report including Haverford entities (CIKs 0000842941, 0001347683, 000130007)
11-05-2026
Claret Asset Management Corp, an institutional investment manager, filed its quarterly 13F-HR on May 11, 2026, disclosing 355 equity positions with a total market value of $837 million as of March 31, 2026. Top holdings include Berkshire Hathaway Inc Class B ($45.7 million), Alphabet Inc Class A ($41.4 million), CGI Inc ($36.6 million), Apple Inc ($28.5 million), and Microsoft Corp ($23.5 million). No period-over-period changes or performance metrics are provided in the filing.
- · All 355 positions reported with sole voting authority and no put/call options.
- · Additional notable holdings: Novo-Nordisk A S ADR (157,347 shares), Royal BK CDA COM (125,077 shares), and Toronto Dominion BK ONT COM NEW (123,937 shares).
11-05-2026
Pinnacle Wealth Planning Services, Inc. filed a 13F-HR report disclosing 2,737 equity positions held solely as of March 31, 2026, with no other voting or investment authority reported. Top holdings include Apple Inc. ($23.4M), Amazon.com Inc. ($11.3M), Alphabet Inc. Class A ($9.1M), and Alphabet Inc. Class C ($5.0M), representing significant technology sector exposure. No quarter-over-quarter changes or performance metrics are provided in the filing.
- · Report period end date: March 31, 2026
- · Filing date: May 11, 2026
- · SEC file number: 028-18382
- · Adviser CRD number: 106817
- · Adviser SEC number: 801-51715
- · Business address: 6 W. 3rd Street, Suite 100, Mansfield, OH 44902
11-05-2026
Constellation Energy reported strong Q1 2026 results with operating revenues surging 64% YoY to $11,122 million and net income attributable to common shareholders rising to $1,590 million from $118 million, reflecting robust performance amid higher energy realizations. The quarter included the completion of the Calpine acquisition, involving $17,507 million in common stock issuance and $2,537 million net cash outflow, significantly expanding the balance sheet to $96,911 million in total assets. However, operating cash flow was $425 million (up 297% YoY but modest relative to earnings), net cash decreased by $2,577 million due to heavy investing and financing activities, and debt levels rose sharply with short-term borrowings at $5,102 million and long-term debt at $16,994 million.
- · Capital expenditures of $1,275 million in Q1 2026, up from $806 million YoY.
- · Proceeds from short-term borrowings: $3,000 million; repayments: $1,500 million.
- · Issuance of long-term debt: $2,770 million; retirement: $5,254 million.
- · Assets held for sale increased to $5,735 million from $126 million QoQ.
- · Gain on sales of assets: $14 million.
11-05-2026
PCJ Investment Counsel Ltd. disclosed its Q1 2026 13F-HR holdings as of March 31, 2026, reporting a total portfolio market value of $352,056,573 across 59 positions, all held with sole voting and investment discretion. The portfolio focuses on Canadian mining, energy, infrastructure, and financial stocks, with largest holdings in Brookfield Business Corp ($30,967,615), CAE Inc ($20,405,110), and Boyd Group Services Inc ($11,988,811). No changes or performance comparisons to prior periods were reported in the filing.
- · All holdings reported with sole shared voting authority (SH SOLE) and no other voting or discretion authority.
- · Filed on May 11, 2026; Filer CIK: 0001426318.
- · Headquartered at 130 King Street West, Suite 1400, Toronto, A6 M5X 1C8, Canada.
11-05-2026
Montis Financial, LLC, an investment adviser based in Waltham, MA, filed its 13F-HR on May 11, 2026, disclosing total holdings valued at $483506877 as of March 31, 2026, across 150 positions, all with sole voting power. Top holdings include Professionally Managed Portfolios Akre Focus ETF (value $42702675), First Trust Exch Traded FD III Instl Pfd Secs (value $34519452), and Schwab Strategic TR US Dividend EQ (value $18260909). No changes or performance metrics are reported in this snapshot filing.
- · Filing period end date: March 31, 2026
- · Filer CIK: 0001844314
- · SEC file number: 028-20655
- · Business address: 230 Third Avenue, Waltham, MA 02451
11-05-2026
Connor, Clark & Lunn Investment Management Ltd. disclosed holdings in 1,526 equity positions totaling $43,404,014,372 as of March 31, 2026, in its 13F-HR filing submitted on May 11, 2026. The portfolio includes significant stakes in technology giants such as Apple Inc. (3,021,296 shares valued at $766,774,712), Amazon.com Inc. (2,447,707 shares valued at $509,783,937), and Alphabet Inc. (Class A: 1,533,694 shares at $441,029,047; Class C: 1,370,812 shares at $393,231,130), alongside positions in healthcare, mining, and financial sectors. No prior period comparisons or performance metrics are provided in the filing.
- · Report period end date: March 31, 2026
- · Filing date: May 11, 2026
- · Filer CIK: 0001596800
- · Business address: 2300-1111 West Georgia Street, Vancouver A1 V6E 4M3
- · SEC file number: 028-16144
11-05-2026
Elequin Capital, LP filed its 13F-HR on May 11, 2026, disclosing institutional holdings as of March 31, 2026, with a diverse portfolio heavily weighted toward cryptocurrency ETFs and other equities. Key positions include Bitwise Solana Staking ETF at $9.28B market value, Bitwise Bitcoin ETF at $8.47B, Fidelity Wise Origin Bitcoin Fund at $5.53B, and Coinbase Global at $4.23B. The filing lists approximately 9,754 holdings across sectors like technology, mining, and fixed income, with no prior quarter data for comparison.
- · Report period end date: 2026-03-31
- · Filing CIK: 0001810873
- · Business address: 1333 Broadway Suite 500, New York, NY 10018
- · Phone: 6468146717
11-05-2026
Timmons Wealth Management, LLC filed its 13F-HR on May 11, 2026, reporting 73 holdings as of March 31, 2026, with a total portfolio value of $49637350. The portfolio is diversified across ETFs from iShares, Vanguard, Schwab Strategic Trust, and others, alongside individual stocks such as Johnson & Johnson, Microsoft, and Apple. No period-over-period changes, performance metrics, or material shifts in holdings were disclosed.
- · SEC file number: 028-26286
- · Adviser CIK: 000165914
- · Business address: 300 North Main St., Attleboro, MA 02703
- · Fiscal year end: 1231
- · No voting authority details beyond SOLE for listed holdings
Get daily alerts with 12 investment signals, 9 risk alerts, 8 opportunities and full AI analysis of all 50 filings
More from: S&P 500 Consumer Staples Sector SEC Filings
🇺🇸 More from United States
View all →May 06, 2026
US Pre-Market SEC Filings Roundup — May 06, 2026
US Pre-Market SEC Filings Roundup
May 06, 2026
New Drug Approvals (Original) — May 06, 2026
New Drug Approvals (Original)
May 06, 2026
Orphan Drug Approvals — May 06, 2026
Orphan Drug Approvals
May 06, 2026
Biotech Small-Cap Approvals — May 06, 2026
Biotech Small-Cap Approvals